Compagnie Lombard Odier S Cm A Dyne Therapeutics, Inc. Transaction History
Compagnie Lombard Odier S Cm A
- $5.66 Billion
- Q2 2024
A detailed history of Compagnie Lombard Odier S Cm A transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Compagnie Lombard Odier S Cm A holds 7,000 shares of DYN stock, worth $236,810. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,000Holding current value
$236,810% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DYN
# of Institutions
201Shares Held
106MCall Options Held
82.7KPut Options Held
24.8K-
Atlas Venture Life Science Advisors, LLC8.02MShares$271 Million37.7% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$265 Million40.83% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$250 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.39MShares$216 Million3.76% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$205 Million3.22% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.75B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...